AP NEWS

Global Endometrial Cancer Therapeutics Market 2018-2022 | Emergence of Immune Therapy to Boost Demand | Technavio

October 9, 2018

LONDON--(BUSINESS WIRE)--Oct 9, 2018-- analysts forecast the global endometrial cancer therapeutics market to grow at a CAGR of over 5% during the forecast period, according to their latest market research report.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181009005925/en/

Technavio analysts forecast the global endometrial cancer therapeutics market to grow at a CAGR of over 5% by 2022. (Graphic: Business Wire)

The emergence of immune therapy is one of the major trends being witnessed in the . Immune therapy also known as biological therapy is a type of cancer treatment that improves the defense mechanism of the body to fight against cancer. It uses substances synthesized by the body or in a laboratory to restore immune system function. Immunotherapy works by hindering or slowing the growth of the cancer cells. Also, it stops from spreading to other parts of the body.

This report is available at a USD 1,000 discount for a limited time only:

According to Technavio analysts, one of the key factors contributing to the growth of the global endometrial cancer therapeutics market is the increasing prevalence of endometrial cancer:

Global endometrial cancer therapeutics market: Increasing prevalence of endometrial cancer

Endometrial cancer is one of the most common gynecological malignancies, the incidence of which is increasing globally. The prevalence rate of endometrial has been rising due to the changing lifestyle. As more than 80% of the endometrial cancers are estrogen related, changing lifestyle and socioeconomic factors that affect the estrogen exposure are related to a recent increase in prevalence rate.

According to a senior analyst at Technavio for research on oncology, “Endometrial cancer is most common in Western countries and is more prevalent in postmenopausal women. As per an article published in the NCB, in 2015, in Romania, endometrial cancer recorded a peak incidence in the age group of 60-64 years, which reached an average value of 8.06 cases per 100,000 women in 2013. Also, 35% of the endometrial cases were diagnosed in their advanced stage, with significantly diminished life expectancy.”

Global endometrial cancer therapeutics market: Segmentation analysis

The global endometrial cancer therapeutics market research report provides market segmentation by product (chemotherapy and hormone therapy) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Of the two major products, the chemotherapy segment held the largest market share in 2017, contributing to close to 74% of the market. This product segment will dominate the global market throughout the forecast period.

The Americas held the largest share of the market in 2017, accounting for more than 44% share. It was followed by EMEA and APAC respectively. The region is expected to continue to dominate the market.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

Market ecosystem Market characteristics Market segmentation analysis

Market Sizing

Market definition Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

Regional comparison Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendors covered Vendor classification Market positioning of vendors Competitive scenario

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20181009005925/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA SOUTH AMERICA AFRICA MIDDLE EAST

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES RESEARCH SCIENCE

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 10/09/2018 12:22 PM/DISC: 10/09/2018 12:22 PM

http://www.businesswire.com/news/home/20181009005925/en

AP RADIO
Update hourly